Cash Flow ImprovementSignificant improvement in free cash flow indicates enhanced cash generation capabilities, providing more flexibility for future investments and operations.

Strong Balance SheetA strong equity position with low financial leverage suggests financial stability, enabling the company to withstand economic fluctuations and invest in growth opportunities.

Operational EfficiencyMaintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.

Bears Say

Declining RevenueA substantial drop in revenue suggests challenges in market demand or competitive positioning, which could impact the company's ability to sustain growth and profitability.

Negative ProfitabilityNegative profitability highlights issues in cost management or pricing strategy, posing risks to the company's financial health and ability to reinvest in its business.

Declining Gross Profit MarginA declining gross profit margin indicates rising costs or pricing pressures, which could erode profitability and limit resources available for growth initiatives.

272 FAQ

What was Mabion SA’s price range in the past 12 months?

Mabion SA lowest stock price was €1.58 and its highest was €2.63 in the past 12 months.

What is Mabion SA’s market cap?

Mabion SA’s market cap is €31.30M.

When is Mabion SA’s upcoming earnings report date?

Mabion SA’s upcoming earnings report date is May 21, 2026 which is in 90 days.

How were Mabion SA’s earnings last quarter?

Mabion SA released its earnings results on Nov 04, 2025. The company reported -€0.157 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.157.

Is Mabion SA overvalued?

According to Wall Street analysts Mabion SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mabion SA pay dividends?

Mabion SA does not currently pay dividends.

What is Mabion SA’s EPS estimate?

Mabion SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mabion SA have?

Mabion SA has 16,162,327 shares outstanding.

What happened to Mabion SA’s price movement after its last earnings report?

Mabion SA reported an EPS of -€0.157 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.526%.

Which hedge fund is a major shareholder of Mabion SA?

Currently, no hedge funds are holding shares in DE:272

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mabion SA

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.